Cancer Clinical Trials: Development and Implementation

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 6, 2007, Pages 1033-1057

  Vail, David M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; LIPOSOME; MITOPODOZIDE; PLACEBO; PYRIDOXINE;

ANIMAL WELFARE; BAYESIAN LEARNING; CANCER RESEARCH; CANCER SURVIVAL; CAT DISEASE; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DOG DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; INFORMED CONSENT; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METHODOLOGY; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOSARCOMA; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SARCOMA; SKIN TOXICITY; TOXICITY TESTING; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; NEOPLASMS; RESEARCH DESIGN;

ANIMALIA;

EID: 35348844567     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.06.007     Document Type: Review

References (65)

1. Mack G.S. Clinical trials going to the dogs; canine program to study tumor treatment, biology. J Natl Cancer Inst 98 3 (2006) 161-162
2. Mack G.S. Cancer researchers usher in dog days of medicine. Nat Med 11 10 (2005) 1018
3. Khanna C., Lindblad-Toh K., Vail D., et al. The dog as a cancer model. Nat Biotechnol 24 9 (2006) 1065-1066
4. Waters D.J., and Wildasin K. Cancer clues from pet dogs. Sci Am 295 6 (2006) 94-101
5. Kummar S., Gutierrez M., Doroshow J.H., et al. Drug development in oncology; classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62 1 (2006) 15-26
6. Kamb A., Wee S., and Lengauer C. Why is cancer drug discovery so difficult. Nat Rev Drug Discov 6 2 (2007) 115-120
7. Kamb A. What's wrong with our cancer models?. Nat Rev Drug Discov 4 2 (2005) 161-165
8. Whitehead J. Stopping clinical trials by design. Nat Rev Drug Discov 3 11 (2004) 973-977
9. Booth B., Glassman R., and Ma P. Oncology trials. Nat Rev Drug Discov 2 8 (2003) 609-610
10. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs: Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4 (1998) 1079-1086
11. Kummar S., Kinders R., Rubinstien L., et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 7 2 (2007) 131-139
12. Potter D.M. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs. J Biopharm Stat 16 5 (2006) 579-604
13. Acevedo P.V., Toppmeyer D.L., and Rubin E.H. Phase I trial design and methodology for anticancer drugs. In: Teicher B.A., and Andrews P.A. (Eds). Anticancer drug development guide. 2nd edition (2004), Humana Press, Totowa (NJ) 351-362
14. Vail D.M. Veterinary Co-Operative Oncology Group-common terminology criteria for adverse events following chemotherapy or biological antineoplastic therapy in dogs and cats. Veterinary and Comparative Oncology 2 4 (2004) 194-213
15. Thamm D.H., Kurzman I.D., King I., et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 11 (2005) 4827-4834
16. ®) in dogs with spontaneous neoplasia. J Vet Intern Med 18 (2004) 536-539
17. ®) for the treatment of canine malignant tumors. J Vet Intern Med 18 (2004) 219-222
18. Khanna C., and Vail D.M. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 3 (2003) 265-273
19. Thamm D.H., MacEwen E.G., Phillips B.S., et al. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother Pharmacol 49 (2002) 251-255
20. Vail D.M., Kravis L.D., Cooley A.J., et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 39 (1997) 410-416
21. Hershey A.E., Kurzman I.D., Bohling C., et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle in a companion animal model. Clin Cancer Res 5 (1999) 2653-2659
22. Otterson G.A., Villalona-Calero M.A., Sharma S., et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 13 4 (2007) 1246-1252
23. Simon R. Optimal two-stage designs for phase II clinical trial. Control Clin Trials 10 1 (1989) 1-10
24. Michaelis L.C., and Ratain M.J. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 13 8 (2007) 2400-2405
25. Gray R., Manola J., Saxman S., et al. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res 12 7 (2006) 1966-1969
26. Lee J.J., and Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23 19 (2005) 4450-4457
27. Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13 (1961) 346-353
28. Fleming T.R. One sample multiple testing procedure for phase AII clinical trials. Biometrics 38 (1982) 143-151
29. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 3 (2000) 205-216
30. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organizations Offset Publication No. 48; 1979.
31. Poirier V.J., Kurzman I.D., Thamm D.K., et al. Liposome-encapsulated doxorubicin (Doxil R) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 16 (2002) 726-731
32. Bergman P.J., McKnight J., Novosad A., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase. Clin Cancer Res 9 (2003) 1284-1290
33. Alexander A.N., Huelsmeyer M.K., Mitzey M., et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 55 (2006) 433-442
34. Vail D.M., Chun R., Thamm D.H., et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4 (1998) 1567-1571
35. Dagher R.N., and Pazdur R. The phase III clinical cancer trial. In: Teicher B.A., and Andrews P.A. (Eds). Anticancer drug development guide. 2nd edition (2004), Humana Press, Totowa (NJ) 401-410
36. Vail D.M., Kurzman I.D., Glawe P.A., et al. Stealth liposomal cisplatin versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 50 (2002) 131-136
37. Friedman L.M., Furberg C.D., and DeMets D.L. The randomization process. Fundamentals of clinical trials. 2nd edition (1985), PSG Publishing, Littleton (MA) 51-69
38. Edwards S., and Braunholtz D. Can unequal be more fair? A response to Andrew Avins. J Med Ethics 26 (2000) 179-182 10.1136/jme.26.3.179
39. Avins A.L. Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics 24 (1998) 401-408
40. Montori V.M., and Guyatt G.H. Intention-to-treat principle. Can Med Assoc J 165 10 (2001) 1339-1341
41. Fergusson D., Aaron S.D., Guyatt G., et al. Post-randomization exclusion: the intention to treat principle and excluding patients from analysis. Br Med J 325 7365 (2002) 652-655
42. Twombly R. Slow start to phase 0 as researchers debate value. J Natl Cancer Inst 98 12 (2006) 804-806
43. Lee J.J., Lieberman R., Sloan J.A., et al. Design considerations for efficient prostate cancer chemoprevention trials. Urology 57 4 Suppl 1 (2001) 206-212
44. o embedded in sequential tests. Stat Med 16 (1997) 465-477
45. Lachin J.M. A review of methods for futility stopping based on conditional power. Stat Med 24 (2004) 2747-2764
46. Berry D.A. Bayesian clinical trials. Nat Rev Drug Discov 5 (2006) 27-36
47. Johns D., and Andersen J.S. Use of predictive probabilities in phase II and phase III clinical trials. J Biopharm Stat 9 (1999) 67-69
48. Berry D.A., and Eick S.G. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 14 (1995) 231-246
49. Thall P.F., Wathen J.K., Bekele B.N., et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22 (2003) 763-780
50. Inoue L.Y., Thall P.F., and Berry D.A. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58 (2002) 823-831
51. Stallard N., Thall P.F., and Whitehead J. Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics 55 (1999) 971-977
52. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy; results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 16 (2005) 3676-3685
53. Stadler W.M. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther 6 4 (2007) 1180-1185
54. Stadler W.M., Rosner G., Small E., et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 23 16 (2005) 3726-3732
55. Rosner G.L., Stadler W., and Ratain M.J. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20 22 (2002) 4478-4484
56. Huang X., Biswas S., Oki Y., et al. A parallel phase I/II clinical trial design for combination therapies. Biometrics (2006) 1-8
57. Maca J. Adaptive seamless phase II/III designs-background, operational aspects and examples. Drug Inf J 40 04 (2006) 463-474
58. Bretz F., Schmidli H., Konig F., et al. Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: general concepts. Biom J 48 4 (2006) 623-634
59. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
60. Jones R.L., and Judson I.R. The development and application of imatinib. Expert Opin Drug Saf 4 2 (2005) 183-191
61. Tsong Y., and Chen W.J. Noninferiority testing beyond simple two-sample comparison. J Biopharm Stat 17 2 (2007) 289-308
62. Cox A.C., Fallowfield L.J., and Jenkins V.A. Communication and informed consent in phase 1 trials: a review of the literature. Support Care Cancer 14 4 (2006) 303-309
63. Jayson G., and Harris J. How participants in cancer trials are chosen: ethics and conflicting interests. Nat Rev Cancer 6 4 (2006) 330-336
64. Albrecht T.L., Franks M.M., and Ruckdesche J.C. Communication and informed consent. Curr Opin Oncol 17 4 (2005) 336-339
65. Morris Animal Foundations. Available at: www.morrisanimalfoundation.org/reports/grants/full_proposal/Established_Investigator_guidelines.pdf.